obstructive sleep apnea News
-
Renowned Sleep Expert Dr. Jerrold Kram to Present New Sleep Apnea Treatment by Sommetrics at SLEEP 2018
SAN DIEGO, Calif. — May 30, 2018 — Sommetrics, a company providing products and services to improve sleep quality, today announced that renowned sleep expert Jerrold Kram, M.D., FCCP, FAASM, will be discussing the company’s new sleep apnea treatment, aerSleepTM, during SLEEP 2018, the 32nd Annual Meeting of the Associated Professional Sleep Societies in Baltimore, Maryland. ...
By Sommetrics
-
Signifier® Medical Ushers In New Era of Treatment for Sleep Apnea and Snoring with FDA Approval of eXciteOSA® Device
The FDA has approved eXciteOSA, the revolutionary first-ever daytime treatment for mild obstructive sleep apnea and snoring. Used for only 20 minutes per day for a period of six weeks and then twice per week, the therapy is clinically proven to improve the quality of sleep by significantly reducing obstructive sleep apnea and snoring. Signifier Medical Technologies, an innovator in the sleep ...
-
FRI Improves Patient Selection for Mandibular Advancement Device Treatment
In a recent published study Functional Respiratory Imaging (FRI) was used to assess Mandibular advancement devices (MAD) mechanisms. MAD are a non-invasive treatment option for patients with obstructive sleep apnea (OSA) and act by increasing the upper airway volume. However, the exact therapeutic mechanism of action remains unclear. In this study 100 OSA patients were prospectively included ...
By Fluidda
-
Nyxoah Announces Participation in the Baird 2021 Global Healthcare Conference
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, and Fabian Suarez, Chief Financial Officer, will participate at the Baird 2021 Global Healthcare ...
By Nyxoah SA
-
Nyxoah Announces Participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, will participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference on from November ...
By Nyxoah SA
-
Sommetrics Completes Study of New Sleep Apnea Treatment in Ethnic Japanese Subjects
VISTA, Calif. — JUNE 25, 2019 — Sommetrics a company dedicated to developing state of the art products to treat obstructive sleep apnea (OSA), today announced the completion of clinical study SOM-014. This trial evaluated the safety, tolerability and effectiveness of the Sommetrics aerSleep™ product in ethnic Japanese subjects with obstructive sleep apnea (OSA). This was a ...
By Sommetrics
-
Nyxoah Announces Participation in the Stifel 2021 Virtual Healthcare Conference
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, will participate at the Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021, ...
By Nyxoah SA
-
Nyxoah Announces Participation in the Cantor 2021 Virtual Global Healthcare Conference
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, will participate at the Cantor 2021 Global Healthcare Conference on Tuesday, September 28, 2021, ...
By Nyxoah SA
-
Nyxoah to present at the Oppenheimer 31st Annual Healthcare Conference
Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces the participation of its management team in the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021. Olivier Taelman, CEO of ...
By Nyxoah SA
-
Nyxoah announces the publication of first positive clinical data in an OSA patient suffering from Complete Concentric Collapse (CCC)
Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces the publication of an article presenting the first case of successful treatment of an OSA patient suffering from Complete Concentric Collapse (CCC) ...
By Nyxoah SA
-
Sommetrics Engages Key West Investments to Raise Additional Capital, Prepares for Commercialization of Sleep Apnea Therapy
SAN DIEGO, Calif. — October 24, 2017 — Sommetrics, a company providing products and services to improve sleep quality, today announced that it has engaged Key West Investments to help raise additional capital. This capital will support the company’s development and commercialization of products to treat disorders of the upper airway such as obstructive sleep apnea and chronic ...
By Sommetrics
-
Sommetrics Selected to Present at the Respiratory Innovation Summit
SAN DIEGO, Calif. — MAY 14, 2019 — Sommetrics, a company providing products and services to improve sleep quality, today announced it has been selected to be one of five companies to present at the airways symposium of the Respiratory Innovation Summit in Dallas on May 17, 2019. This Summit is a yearly event held in advance of the American Thoracic Society’s International ...
By Sommetrics
-
Nyxoah Announces Submission of Draft Registration Statement for Proposed Public Listing in the United States
Nyxoah SA (Euronext Brussels: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that it has confidentially submitted a draft Registration Statement on Form F-1 to the Securities and Exchange Commission (the "SEC") relating to the ...
By Nyxoah SA
-
Nyxoah to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which will be held virtually ...
By Nyxoah SA
-
Nyxoah appoints new CFO
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Loïc Moreau will join Nyxoah as CFO as of January 1, 2022. Loïc will join Nyxoah from GSK, where he held leadership roles in ...
By Nyxoah SA
-
eXciteOSA® Daytime Sleep Apnea Therapy Device Surpasses 50,000 Patient Session Milestone
Signifier Medical Technologies Ltd, an innovator in the sleep-disordered breathing market, announced today that it has hit the 50,000 therapy session milestone with its innovative eXciteOSA® sleep device. Following FDA authorization and clearance for marketing in February 2021, eXciteOSA has been quickly adopted by physicians and patients alike. The first of its kind, eXciteOSA is a daytime ...
-
Inspire Medical Systems, Inc. Announces Two Additional Coverage Policies from Blue Cross Blue Shield Healthcare Plans
MINNEAPOLIS, Minnesota – August 17, 2020 – Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), announced today that two additional Blue Cross Blue Shield (“BCBS”) plans ...
-
Nyxoah Announces CE-Mark Indication Approval to Treat Complete Concentric Collapse (CCC) Patients
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that DEKRA Notified Body has approved the Company’s proposed indication for the Genio® system to treat patients with a Complete ...
By Nyxoah SA
-
Nyxoah Announces U.S. FDA Breakthrough Device Designation Granted for the Genio® System for Obstructive Sleep Apnea and Complete Concentric Collapse
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the U.S. Food and Drug Administration (FDA) has granted the Genio® bilateral hypoglossal nerve stimulation system Breakthrough Device ...
By Nyxoah SA
-
Signifier Medical Receives Prestigious 2020 GOOD DESIGN Award for Superior Design Excellence
Signifier Medical Technologies, an innovator in the sleep disordered breathing market, today announced that eXciteOSA®, the first and only daytime intraoral neuromuscular stimulation device for treating mild obstructive sleep apnea and snoring, has received the prestigious GOOD DESIGN® Award in the Medical category. The device was recently approved by the U.S. Food and Drug Administration ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you